Cargando…
Targeting Viral Ion Channels: A Promising Strategy to Curb SARS-CoV-2
SARS-CoV-2 is the etiological agent COVID-19, one of the most impactful health crises afflicting humanity in recent decades. While research advances have yielded several treatment and prevention options, the pandemic is slow to abate, necessitating an expansion of our treatment arsenal. As a member...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029588/ https://www.ncbi.nlm.nih.gov/pubmed/35455392 http://dx.doi.org/10.3390/ph15040396 |
_version_ | 1784691915882496000 |
---|---|
author | Singh, Anamika Arkin, Isaiah T. |
author_facet | Singh, Anamika Arkin, Isaiah T. |
author_sort | Singh, Anamika |
collection | PubMed |
description | SARS-CoV-2 is the etiological agent COVID-19, one of the most impactful health crises afflicting humanity in recent decades. While research advances have yielded several treatment and prevention options, the pandemic is slow to abate, necessitating an expansion of our treatment arsenal. As a member of the coronaviridae, SARS-CoV-2 contains several ion channels, of which E and 3a are the best characterized. Since ion channels as a family are excellent drug targets, we sought to inhibit both viroporins as a means to curb infectivity. In a previous targeted study, we identified several blockers to each channel from an extensive drug repurposing library. Herein, we examined the ability of said compounds on the whole virus in cellulo. Gratifyingly, many of the blockers exhibited antiviral activity in a stringent assay examining protection from viral-driven death. In particular, darapladib and flumatinib, both 3a blockers, displayed potent antiviral activity. Furthermore, appreciable synergism between flumatinib and several E blockers was identified in a concentration regime in which the compounds are present in human plasma following oral administration. Taken together, targeting ion channels represents a promising approach to both augment and complement our antiviral arsenal against COVID-19. |
format | Online Article Text |
id | pubmed-9029588 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90295882022-04-23 Targeting Viral Ion Channels: A Promising Strategy to Curb SARS-CoV-2 Singh, Anamika Arkin, Isaiah T. Pharmaceuticals (Basel) Article SARS-CoV-2 is the etiological agent COVID-19, one of the most impactful health crises afflicting humanity in recent decades. While research advances have yielded several treatment and prevention options, the pandemic is slow to abate, necessitating an expansion of our treatment arsenal. As a member of the coronaviridae, SARS-CoV-2 contains several ion channels, of which E and 3a are the best characterized. Since ion channels as a family are excellent drug targets, we sought to inhibit both viroporins as a means to curb infectivity. In a previous targeted study, we identified several blockers to each channel from an extensive drug repurposing library. Herein, we examined the ability of said compounds on the whole virus in cellulo. Gratifyingly, many of the blockers exhibited antiviral activity in a stringent assay examining protection from viral-driven death. In particular, darapladib and flumatinib, both 3a blockers, displayed potent antiviral activity. Furthermore, appreciable synergism between flumatinib and several E blockers was identified in a concentration regime in which the compounds are present in human plasma following oral administration. Taken together, targeting ion channels represents a promising approach to both augment and complement our antiviral arsenal against COVID-19. MDPI 2022-03-24 /pmc/articles/PMC9029588/ /pubmed/35455392 http://dx.doi.org/10.3390/ph15040396 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Singh, Anamika Arkin, Isaiah T. Targeting Viral Ion Channels: A Promising Strategy to Curb SARS-CoV-2 |
title | Targeting Viral Ion Channels: A Promising Strategy to Curb SARS-CoV-2 |
title_full | Targeting Viral Ion Channels: A Promising Strategy to Curb SARS-CoV-2 |
title_fullStr | Targeting Viral Ion Channels: A Promising Strategy to Curb SARS-CoV-2 |
title_full_unstemmed | Targeting Viral Ion Channels: A Promising Strategy to Curb SARS-CoV-2 |
title_short | Targeting Viral Ion Channels: A Promising Strategy to Curb SARS-CoV-2 |
title_sort | targeting viral ion channels: a promising strategy to curb sars-cov-2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029588/ https://www.ncbi.nlm.nih.gov/pubmed/35455392 http://dx.doi.org/10.3390/ph15040396 |
work_keys_str_mv | AT singhanamika targetingviralionchannelsapromisingstrategytocurbsarscov2 AT arkinisaiaht targetingviralionchannelsapromisingstrategytocurbsarscov2 |